Size : | Price | Quantity | |
---|---|---|---|
10 mg | $30.00 | ||
50 mg | $100.00 |
BADGE (1675-54-3) is a PPARγ antagonist with μM affinity in 3T3-L1 and 3T3-F442A preadipocyte cells. Selective over PPARδ and PPARα. Antagonizes the ability of rosiglitazone to stimulate transcriptional activity of PPARγ and abolishes its anti-inflammatory effects in a mouse model.1 Induces apoptosis via PPARγ-independent mechanisms.2 Induces adipogenesis in human and mouse mesenchymal stromal stem cells and in mouse 3T3-L1 preadipocytes at low nM concentrations via a PPARγ independent mechanism.3 Increases osteoblastogenesis and bone mass in a mouse model.4 Active in vivo.
References/Citations:
1) Cuzzocrea et al. (2004), Rosiglitazone , a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation; Eur. J. Pharmacol., 483 79
2) Fehlberg et al. (2003), Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO; Br. J. Pharmacol., 139 495
3) Chamorro-Garcia et al. (2012), Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism; Environ. Health Perspect., 120 984
4) Duque et al. (2013), Pharmacological inhibition of PPARgamma increases osteoblastogenesis and bone mass in male C57BL/6 mice; J. Bone Miner. Res., 28 639
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
BADGE (1675-54-3) is a PPARγ antagonist with μM affinity in 3T3-L1 and 3T3-F442A preadipocyte cells. Selective over PPARδ and PPARα. Antagonizes the ability of rosiglitazone to stimulate transcriptional activity of PPARγ and abolishes its anti-inflammatory effects in a mouse model.1 Induces apoptosis via PPARγ-independent mechanisms.2 Induces adipogenesis in human and mouse mesenchymal stromal stem cells and in mouse 3T3-L1 preadipocytes at low nM concentrations via a PPARγ independent mechanism.3 Increases osteoblastogenesis and bone mass in a mouse model.4 Active in vivo.
References/Citations:
1) Cuzzocrea et al. (2004), Rosiglitazone , a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation; Eur. J. Pharmacol., 483 79
2) Fehlberg et al. (2003), Bisphenol A diglycidyl ether-induced apoptosis involves Bax/Bid-dependent mitochondrial release of apoptosis-inducing factor (AIF), cytochrome c and Smac/DIABLO; Br. J. Pharmacol., 139 495
3) Chamorro-Garcia et al. (2012), Bisphenol A diglycidyl ether induces adipogenic differentiation of multipotent stromal stem cells through a peroxisome proliferator-activated receptor gamma-independent mechanism; Environ. Health Perspect., 120 984
4) Duque et al. (2013), Pharmacological inhibition of PPARgamma increases osteoblastogenesis and bone mass in male C57BL/6 mice; J. Bone Miner. Res., 28 639
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.